Physician profile
Charlotte Marie Agnone
NPI 1255446894
$32,087.15
in general payments reported to CMS, 2019-2025
23 companies · $95.61 in 2025
The $95.61 reported for 2025 was more than what a typical Integrative Medicine provider received nationally (typical 2025 total: $57.65).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $77.16 · 2021: $183 · 2022: $282 · 2023: $370 · 2024: $703 · 2025: $95.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $30,000.00 | 2019 | |
| Horizon Therapeutics Plc | $268.06 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $241.31 | 2019-2024 | Tecnis Iol |
| Allergan, INC. | $179.06 | 2019-2021 | |
| Abbvie INC. | $173.11 | 2023-2024 | Xen Glaucoma Treatment System, Lumigan, Alphagan P |
| Alcon Vision LLC | $156.90 | 2022-2024 | Clareon, Acrysof Iq Panoptix Uv Iol, Wavelight Refractive Suite |
| Aerie Pharmaceuticals, INC. | $147.95 | 2019-2021 | |
| Amgen INC. | $142.86 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $136.49 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $119.42 | 2024 | Xdemvy |
| Rxsight INC | $105.18 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $95.17 | 2022-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.61 | 2020-2021 | |
| Glaukos Corporation | $39.19 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $36.07 | 2022-2024 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $32.26 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $27.18 | 2021 | |
| Sight Sciences, INC. | $26.78 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $22.92 | 2023 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Harrow Eye, LLC | $21.63 | 2024 | Vevye |
| Coopervision INC. | $19.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.80 | 2019 | |
| New World Medical,INC. | $13.55 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlotte Agnone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.